Reflex UroVysion testing in suspicious urine cytology cases

Cancer Cytopathology

Volumn 117, Issue 1, 2009, Pages 7-14

  Ferra, Susana ^a   Denley, Ryan ^a   Herr, Harry ^a   Dalbagni, Guido ^a   Jhanwar, Suresh ^a   Lin, Oscar ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytology; Suspicious; Urothelial carcinoma; UroVysion

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER TUMOR; CYSTOSCOPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 65349095267     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20016     Document Type: Article

References (32)

1. World Health Organzation. Pathology and genetics of tumors of the urinary system and male genital organs. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2004:90-157.
2. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.
3. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311-322.
4. Veeramachaneni R, Nordberg ML, Shi R, Herrera GA, Turbat-Herrera EA. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol. 2003;28: 301-307.
5. Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urology. 2006;67(3 suppl 1):25-33; discussion 33-4.
6. Maier U, Simak R, Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol. 1995;48:314-317.
7. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol. 1999;161:388-394.
8. Sarosdy MF, Hudson MA, Ellis WJ, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 1997;50:349-353.
9. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007;51:1275-1280; discussion 1280.
10. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998;52: 398-402.
11. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors: II. Cytogenetics and molecular genetics of bladder cancer. J Urol. 1994;151:545-560.
12. Sidransky D, Messing E. Molecular genetics and biochemical mechanisms in bladder cancer: oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am. 1992;19:629-639.
13. Knowles MA. Molecular genetics of bladder cancer. Br J Urol. 1995;75(suppl 1):57-66.
14. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene. 1993;8:1083-1085.
15. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784-788.
16. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res. 1995;55:5213-5216.
17. Ruppert JM, Tokino K, Sidransky D. Evidence for 2 bladder cancer suppressor loci on human chromosome 9. Cancer Res. 1993;53:5093-5095.
18. Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1997;19:84-89.
19. Orlow I, Lacombe L, Hannon GJ, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst. 1995;87:1524-1529.
20. Richter J, Jiang F, Gorog JP, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997;57:2860-2864.
21. Sasaki K, Hamano K, Kinjo M, Hara S. Intratumoral heterogeneity in DNA ploidy of bladder carcinomas. Oncology. 1992;49:219-222.
22. Shackney SE, Berg G, Simon SR, et al. Origins and clinical implications of aneuploidy in early bladder cancer. Cytometry. 1995;22:307-316.
23. Zhao J, Richter J, Wagner U, et al. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res. 1999;59:4658-4661.
24. Billerey C, Lamy B, Bittard H, Rozan S, Carbillet JP. Flow cytometry versus urinary cytology in the diagnosis and follow-up of bladder tumors: critical review of a 5-year experience. World J Urol. 1993;11:156-160.
25. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116-123.
26. Sauter G, Gasser TC, Moch H, et al. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol Res. 1997;25(suppl 1):S37-S43.
27. Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis Uro-Vysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002;167:2001-2006.
28. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768-1775.
29. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168: 1950-1954.
30. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295-301.
31. Friedrich MG, Toma MI, Hellstern A, et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int. 2003;92:911-914.
32. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79-86.